In February, the Federal Trade Commission settled with pharmaceutical benefits manager (PBM) Express Scripts. The FTC had sued Express Scripts and two other large PBMs under the long dormant Section 5 of the FTC Act, which targets “unfair methods of competition.” The settlement suggests that the FTC may succeed in addressing the convoluted contracts between PBMs, drug manufacturers, health insurers, and employers that drive up drug prices for Americans. It also opens unchartered territory for antitrust enforcement and the limits of Section 5, argue Fiona Scott Morton and Mariah Smith.

In new research, Renuka Diwan, Paul Eliason, Riley League, Ryan C. McDevitt, James W. Roberts, and Jetson Leder-Luis investigate how Medicare’s shift to a competitive bidding system to reduce prices has inadvertently shifted market share to fraudulent suppliers.

Antitrust authorities increasingly assess mergers through the lens of innovation, particularly in research-intensive sectors such as pharmaceuticals. In new research, Carmine Ornaghi and Lorenzo Cassi show how mergers disrupt human capital and reduce innovation in what they call manslaughter acquisitions.

In new research, Martin Schmalz and Jin Xie examine how shareholder preferences influence the United States pharmaceutical industry. They find that generic-drug manufacturers sometimes harm their firms’ own value when doing so benefits shareholder portfolios, who frequently have stakes in competing brand-name firms.

In new research, Luca Macedoni and Ariel Weinberger argue that large firms are more likely to lobby in favor of strict industry regulations when they can reduce competition by imposing high fixed costs on smaller, less-profitable firms.

In new research, Ido Baum, Leszek Balcerowicz, Jakub Karnowski and Andrzej Rzońca assess how Poland achieved economic growth with a populist government. They argue that the economic success is misleading and Poland’s leading party passed harmful policies that affect the country’s long-term growth opportunities. 

An accounting rule introduced by the Financial Accounting Standards Board in 2016 was designed to address a flaw in the previous regime that contributed to the 2008 Financial Crisis. However, this same rule is enabling the circuit of investments that flows from Big Tech companies to artificial intelligence startups, whose increased valuation from these investments increases the value of the Big Tech companies, which they can then reinvest in the AI startups. The risk is an AI bubble that, if it pops, will also blow up Americans’ savings, writes Hera Hyeonseo Lee.

In new research, Louis Pape and Michelangelo Rossi find that the European Union’s Digital Markets Act’s prohibition on self-preferencing had little effect on the popularity of Google Maps relative to competitors. User preference for the incumbent service appears to outweigh frictional barriers to access.